Can I legally buy cosyntropin in the EU online?

No. Cosyntropin is not authorised in any EU member state. Purchasing it online—whether from EU or non-EU vendors—is illegal and carries criminal penalties for both buyer and seller in most jurisdictions. Online vendors claiming to sell cosyntropin are operating outside the law.

Can my doctor prescribe cosyntropin in the EU?

Not as a routine medication. However, a physician may request cosyntropin through compassionate use (named patient use) pathways by applying to the EMA or national regulatory authority, but this is rarely granted and requires documented medical necessity and lack of alternatives.

Is cosyntropin ever used in EU clinical trials?

Yes, cosyntropin may be supplied to participants in approved clinical trials under EU Regulation 536/2014, provided the trial has ethics committee approval and proper regulatory oversight. This is a distinct, legal pathway separate from marketed medicines.

Why is cosyntropin approved in the US but not the EU?

Regulatory approval is jurisdiction-specific. The FDA approved cosyntropin decades ago, but sponsors have not pursued EU authorisation, likely due to limited commercial incentive and the high cost of the approval process. Different regions can have vastly different regulatory landscapes for the same compound.

What diagnostic alternatives exist in the EU if cosyntropin is unavailable?

EU clinicians may use insulin tolerance tests, metyrapone tests, or other ACTH-based assays to evaluate adrenal function. Your healthcare provider can recommend the most appropriate diagnostic approach based on clinical need and local availability.

Cosyntropin Legal Status in the EU: What You Need to Know

Cosyntropin is a synthetic peptide that mimics adrenocorticotropic hormone (ACTH), used in diagnostic testing for adrenal function. In the United States, the FDA has approved cosyntropin as a prescription medication. However, cosyntropin is not authorised by the European Medicines Agency (EMA) for marketing or use in the European Union. This regulatory gap means that EU residents cannot legally obtain cosyntropin through standard pharmaceutical channels, even though it remains a valuable diagnostic tool. Understanding why cosyntropin lacks EU authorisation—and what regulatory pathways exist—is essential for patients, clinicians, and researchers working across borders.

Regulatory Status: Not Authorised in the EU

Cosyntropin holds no marketing authorisation from the European Medicines Agency (EMA). This means it is not a licensed medicine in any EU member state. Unlike the United States, where the FDA approved cosyntropin as a synthetic corticotropin product, the EMA has not completed a centralised approval procedure for this compound.

The distinction is critical: "not authorised" does not mean "illegal to possess in all circumstances." Rather, it means cosyntropin cannot be marketed, sold, or distributed as a finished pharmaceutical product within the EU without specific regulatory permission.

Why Isn't Cosyntropin Authorised in Europe?

The absence of EU authorisation reflects several regulatory realities:

1. Limited Commercial Interest

Cosyntropin is a niche diagnostic agent. The European pharmaceutical market has smaller incentives for sponsors to pursue centralised EMA approval compared to larger therapeutic markets. Approval requires significant investment in clinical trials, dossier preparation, and regulatory submissions—costs that must be justified by expected market revenue.

2. Divergent Regulatory Pathways

The FDA and EMA use different review standards and timelines. A compound approved in the US does not automatically qualify for EU approval. Sponsors must submit separate applications, conduct studies to meet EMA requirements, and satisfy European safety and efficacy standards independently.

3. Historical Precedent

Many older diagnostic peptides and hormones were developed and approved in the US decades ago, before EMA centralised procedures became standard. Sponsors of these compounds rarely invest in retrospective EU approval because the market opportunity has diminished.

Regulatory Classification in the EU

Under EU pharmaceutical law (Directive 2001/83/EC and Regulation 726/2004), cosyntropin would be classified as a human medicinal product requiring authorisation before marketing. Because no authorisation exists, the compound falls outside the legal framework for approved medicines.

This differs from research compounds or investigational agents, which may be supplied under different regulatory provisions for clinical trial purposes. EU Regulation 536/2014 governs clinical trials, allowing cosyntropin to be used in formally approved research settings with appropriate ethics committee oversight.

Practical Implications for EU Residents

Hospital and Clinical Settings

Some EU hospitals and diagnostic laboratories may access cosyntropin under specific circumstances:

Named Patient Use (Compassionate Use): Under EMA exceptional circumstances provisions, a physician might request cosyntropin for an individual patient when no alternative diagnostic test is suitable. This requires EMA authorisation on a case-by-case basis and is rare.
Clinical Trials: If cosyntropin is being investigated in an approved trial, participants may receive it under trial protocols.
Imported from Licensed Markets: Some EU member states permit importing medicines licensed in other countries ("parallel importation") if the source is regulated. However, cosyntropin's lack of authorisation anywhere in Europe limits this option.

Pharmacy Supply

EU pharmacies cannot dispense cosyntropin as a finished product because it lacks a marketing authorisation number (often called a "registration number"). Attempts to supply it would violate pharmaceutical distribution regulations in every member state.

For comparison, related peptide diagnostics like synthetic ACTH analogues may face similar barriers in specific markets, illustrating how regulatory status varies by jurisdiction and compound.

Enforcement and Penalties

National regulatory authorities in EU member states—such as the UK's MHRA (before Brexit) and now under post-Brexit rules—actively monitor for unlicensed medicine distribution. Penalties for supplying unauthorised medicines include:

Criminal prosecution for vendors or importers
Fines up to millions of euros (depending on member state and severity)
Seizure of products
Suspension or revocation of pharmacy or distributor licenses

These enforcement mechanisms are designed to protect patient safety by ensuring only authorised, quality-assured products reach consumers.

How This Compares to the United States

In the US, cosyntropin is fully FDA-approved and available by prescription. Clinicians routinely use it for the cosyntropin stimulation test—a standard diagnostic procedure to assess adrenal insufficiency. The difference underscores how approval status is jurisdiction-specific; a medicine approved in one region may be unavailable or unapproved in another.

Other peptides show similar divergence. AOD-9604, for instance, has different regulatory statuses across markets, reflecting the complexity of global peptide regulation.

Regulatory History and Future Outlook

There is no evidence that cosyntropin's sponsors have filed for centralised EMA approval, nor are there published plans to do so. The compound has been available in the US for decades, yet EU authorisation has never materialised. This suggests the commercial case for EU approval is insufficient to justify the regulatory effort.

If a sponsor were to pursue approval, the process would likely take 2–3 years and cost millions of euros, including:

Preparation of a comprehensive dossier (quality, safety, efficacy data)
Scientific advice from EMA (optional but recommended)
Formal submission via the centralised procedure
EMA Committee for Medicinal Products for Human Use (CHMP) review
Final European Commission decision

Alternatively, member states could authorise cosyntropin under national procedures, but this is unlikely without EMA-level momentum.

What Patients and Clinicians Should Know

For Patients: If you are in the EU and have been prescribed cosyntropin or advised to take a cosyntropin stimulation test, your healthcare provider may need to arrange alternative diagnostic tests or seek compassionate use authorisation. Do not attempt to import cosyntropin from outside the EU; doing so is illegal and poses safety risks.

For Clinicians: When managing patients who require adrenal testing, be aware of local diagnostic alternatives. Insulin tolerance tests and other ACTH-based assays may be available. If cosyntropin is deemed essential, initiate formal compassionate use requests through your national regulatory authority or hospital ethics committee.

For Researchers: Clinical trials using cosyntropin in EU sites must follow EU Clinical Trials Regulation 536/2014 and obtain ethics committee approval. This is a legitimate pathway for research but requires formal protocols and monitoring.

Related Peptide Regulatory Landscapes

Cosyntropin's absence from EU markets is part of a broader pattern affecting many peptide therapeutics. Some peptides, like Abaloparatide, have achieved approval in multiple jurisdictions, including both the US and select EU markets, while others remain unavailable. Understanding these differences is crucial for patients and professionals navigating the global peptide landscape.

Another example is Balixafortide, which pursued regulatory approval in the EU through different pathways than simpler diagnostics, reflecting the distinct challenges of peptide drug development.

Summary

Cosyntropin is not legally authorised in the European Union under any marketing authorisation. While it remains a valuable diagnostic tool—approved and widely used in the US—EU regulations do not permit its sale or distribution as a finished pharmaceutical product. Limited commercial interest, differences in regulatory requirements, and the age of the compound have all contributed to the absence of EMA approval. EU residents requiring cosyntropin-based diagnostics should consult healthcare providers about alternatives or formal compassionate use channels. Attempts to import or supply cosyntropin without authorisation violate EU law and carry serious legal consequences.

Cosyntropin Legal Status in the EU: Regulatory Overview & Market Access